Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,800 Publications201,349 Funding7,267 Clinical research143

Loading search results…

Browse

Scholars8,800 Publications201,349 Funding7,267 Clinical research143

FiltersClear all

Status

Terminated143
Recruiting1,209
Not yet recruiting11
Enrolling by invitation20
Active, not recruiting553
Completed895

Study type

Interventional132
Observational11

Phase

Phase 243
Phase 333
Phase 121
Not applicable13
Not reported11
Phase 1/29

Investigator

Gail J Roboz7
Ruben Niesvizky5
Pinkal Desai4
Sebastian A. Mayer4
Sonal Kumar4

Show all 50Show fewer

Department

Medicine104
Pediatrics10
Psychiatry5
Radiology5
Neurology4

Show all 13Show fewer

Condition

Leukemia, Myeloid, Acute12
Myelodysplastic Syndromes6
Prostatic Neoplasms6
Recurrence6
Multiple Myeloma5

Intervention type

Drug107
Other18
Biological17
Device11
Procedure7
Behavioral5

Sponsor type

Industry95
WCM (investigator-initiated)27
Other academic10
NIH9
Other federal1
Cooperative group1

Start date

Has results posted88

Terminated×Clear all

Showing 1–20 of 143 studiesSort:

TerminatedInterventional · Phase 3NCT02901626 ↗
A Randomized Trial of Pessary in Singleton Pregnancies With a Short Cervix
Daniel W SkupskiPI
Intervention
Device: Arabin Cervical Pessary
Dates
Feb 2017 – Apr 2022

FiltersClear all

Status

Terminated143
Recruiting1,209
Not yet recruiting11
Enrolling by invitation20
Active, not recruiting553
Completed895

Study type

Interventional132
Observational11

Phase

Phase 243
Phase 333
Phase 121
Not applicable13
Not reported11
Phase 1/29

Investigator

Gail J Roboz7
Ruben Niesvizky5
Pinkal Desai4
Sebastian A. Mayer4
Sonal Kumar4

Show all 50Show fewer

Department

Medicine104
Pediatrics10
Psychiatry5
Radiology5
Neurology4

Show all 13Show fewer

Condition

Leukemia, Myeloid, Acute12
Myelodysplastic Syndromes6
Prostatic Neoplasms6
Recurrence6
Multiple Myeloma5

Intervention type

Drug107
Other18
Biological17
Device11
Procedure7
Behavioral5

Sponsor type

Industry95
WCM (investigator-initiated)27
Other academic10
NIH9
Other federal1
Cooperative group1

Start date

Has results posted88

Terminated×Clear all

Showing 1–20 of 143 studiesSort:

TerminatedInterventional · Phase 3NCT02901626 ↗
A Randomized Trial of Pessary in Singleton Pregnancies With a Short Cervix
Daniel W SkupskiPI
Intervention
Device: Arabin Cervical Pessary
Dates
Feb 2017 – Apr 2022

Phase 4

Phase 2/34

Anna C Pavlick3
Catherine McGuinn3
Catherine Butkus Small3
Cora Sternberg3
Harini Sarva3
John Allan3
Marshall J. Glesby3
Manish A Shah3
Ellen K. Ritchie3
Robert J. Kaner3
Robert S. Brown3
Tsiporah B Shore3
Abhishek Jaywant2
Ashish Saxena2
Anna Podolanczuk2
Alexander Drelick2
Barbara Ma2
Dana Jeremy Lukin2
Holly G Prigerson2
Evelyn M. Horn2
James E. Ip2
Jean W. Pape2
Massimo Cristofanilli2
Maria Teresa DeSancho2
Scott T. Tagawa2
Arun B. Jesudian1
Alexandra Gomez Arteaga1
Ana M. Molina1
Anthony Smith1
Bassem M Masri1
Christine Ann Garcia1
Christopher Agrusa1
Cheguevara Afaneh1
Christopher Lau1
Christine M Salvatore1
Charles Anthony Mack1
Carrie Johnston1
Conor Liston1
Carl V. Crawford1
Darshana M Dadhania1
David M Nanus1
Doru Paul1
Douglas S Scherr1
Daniel W Skupski1
Emily Weg1

Surgery4

Obstetrics and Gynecology3

Cardiothoracic Surgery2

Urology2

Dermatology1

Neurological Surgery1

Radiation Oncology1

Rehabilitation Medicine1

Show all 50

Show fewer

COVID-194
Carcinoma, Non-Small-Cell Lung4
Melanoma4
Pulmonary Arterial Hypertension4
Atrial Fibrillation3
Carcinoma, Transitional Cell3
Colitis, Ulcerative3
Esophageal Squamous Cell Carcinoma3
Graft vs Host Disease3
HIV Infections3
Hematologic Neoplasms3
Hemophilia A3
Idiopathic Pulmonary Fibrosis3
Leukemia, Lymphocytic, Chronic, B-Cell3
Leukemia, Myelomonocytic, Chronic3
Lymphoma, Large B-Cell, Diffuse3
Non-alcoholic Fatty Liver Disease3
Parkinson Disease3
Parkinson Disease 4, Autosomal Dominant Lewy Body3
Squamous Cell Carcinoma of Head and Neck3
Aortic Valve Stenosis2
Carcinoma, Renal Cell2
Depression2
Disease Progression2
Heart Failure2
Hypertension, Pulmonary2
Leukemia2
Liver Cirrhosis2
Lymphoma, Non-Hodgkin2
Mpox, Monkeypox2
Myeloproliferative Disorders2
Neoplasms2
Precursor Cell Lymphoblastic Leukemia-Lymphoma2
Pulmonary Fibrosis2
Respiratory Syncytial Virus Infections2
Small Cell Lung Carcinoma2
Thymoma2
Urinary Bladder Neoplasms2
Uterine Cervical Neoplasms2
Acquired Immunodeficiency Syndrome1
Adenoviridae Infections1
Adrenal Insufficiency1
Adrenoleukodystrophy1
Alzheimer Disease1
Anemia1

Dietary supplement

Radiation3

Combination product2

Diagnostic test2

· Results posted

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Develop

Short CervixPreterm Delivery

TerminatedInterventional · Phase 3NCT02999854 ↗

A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy

Sebastian A. MayerPI

Intervention: Biological: ATIR101 · Drug: Cyclophosphamide · Procedure: T-cell depleted HSCT from a related, haploidentical donor · Procedure: T-cell replete HSCT from a related, haploidentical donor
Dates: Nov 2017 – Nov 2021· Results posted
Sponsor: Kiadis Pharma

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome

TerminatedInterventional · Phase 2NCT03107871 ↗

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial

Christine M SalvatorePI

Intervention: Drug: Valganciclovir · Drug: Simple Syrup
Dates: Aug 2018 – Aug 2022· Results posted
Sponsor: University of Utah

Cmv CongenitalCMVCongenital Cmv+2 more

TerminatedInterventional · Phase 1/2NCT03176277 ↗

A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes

Gail J RobozPI

Intervention: Drug: ONO-7475 3mg once daily · Drug: ONO-7475 6mg once daily · Drug: ONO-7475 10mg once daily · Drug: ONO-7475 6mg + Venetoclax (70-400mg)
Dates: Jun 2017 – Dec 2022· Results posted
Sponsor: Ono Pharmaceutical Co., Ltd

Acute LeukemiaMyelodysplastic Syndromes

TerminatedInterventional · Phase 1NCT03218683 ↗

A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies

Pinkal DesaiPI

Intervention: Drug: AZD5991 · Drug: AZD5991 + Venetoclax
Dates: Aug 2017 – Oct 2021
Sponsor: AstraZeneca Pharmaceuticals LP

Relapsed or Refractory Acute Myeloid Leukemia (AML)

TerminatedInterventional · Phase 1NCT03248479 ↗

A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies

Ellen K. RitchiePI

Intervention: Drug: Magrolimab · Drug: Azacitidine
Dates: Sep 2017 – Sep 2023· Results posted
Sponsor: Forty Seven, Inc.

Hematological Malignancies

TerminatedInterventional · Phase 3NCT03267108 ↗

A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD

Robert J. KanerPI

Intervention: Combination product: INOpulse® · Combination product: Placebo · Combination product: Open Label Extension
Dates: Dec 2020 – Jun 2023
Sponsor: Bellerophon Pulse Technologies LLC

Pulmonary FibrosisPulmonary Hypertension

TerminatedInterventional · Phase 2NCT03318939 ↗

A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Christine Ann GarciaPI

Intervention: Drug: Poziotinib
Dates: Oct 2017 – Apr 2023· Results posted
Sponsor: Spectrum Pharmaceuticals, Inc.

NSCLC

TerminatedInterventional · Phase 4NCT03361137 ↗

A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Catherine McGuinnPI

Intervention: Drug: Emicizumab
Dates: Jun 2018 – Mar 2020· Results posted
Sponsor: Genentech, Inc.

Hemophilia A

TerminatedInterventional · Phase 3NCT03464019 ↗

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 and RAPID Studies

James E. IpPI

Intervention: Drug: Etripamil · Drug: Placebo · Drug: Etripamil Test Dose
Dates: Jun 2018 – Jan 2023· Results posted
Sponsor: Milestone Pharmaceuticals

Paroxysmal Supraventricular Tachycardia

TerminatedInterventional · Phase 3NCT03504917 ↗

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

Jeremy Veenstra-VanderWeelePI

Intervention: Drug: Balovaptan · Drug: Placebo
Dates: Aug 2018 – Mar 2020· Results posted
Sponsor: Research Foundation for Mental Hygiene, Inc.

Autism Spectrum Disorder

TerminatedInterventional · Not applicableNCT03510988 ↗

Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer

Katerina DodelzonPI

Intervention: Diagnostic test: Hybrid breast FDG PET/MRI
Dates: Mar 2018 – Mar 2020· Results posted
Sponsor: Weill Medical College of Cornell University

Newly Diagnosed Breast Cancer

TerminatedInterventional · Phase 3NCT03561090 ↗

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors

Philip KatzPI

Intervention: Drug: IW-3718 · Drug: placebo · Drug: Standard-dose PPIs QD
Dates: Jun 2018 – Oct 2020· Results posted
Sponsor: Ironwood Pharmaceuticals, Inc.

Gastroesophageal Reflux Disease (GERD)

TerminatedInterventional · Phase 1/2NCT03572634 ↗

A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)

John AllanPI

Intervention: Drug: TP-0903 · Combination product: TP-0903 and ibrutinib combination therapy
Dates: Jun 2019 – Jan 2020· Results posted
Sponsor: Tolero Pharmaceuticals Inc.

Chronic Lymphocytic LeukemiaCLLSLL+1 more

TerminatedInterventional · Phase 1NCT03582033 ↗

A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: SEA-BCMA · Drug: dexamethasone · Drug: pomalidomide
Dates: Nov 2018 – Nov 2023· Results posted
Sponsor: Seattle Genetics, Inc.

Multiple Myeloma

TerminatedInterventional · Phase 2NCT03606174 ↗

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Cora SternbergPI

Intervention: Drug: Sitravatinib · Drug: Nivolumab · Drug: Pembrolizumab · Drug: Enfortumab vedotin
Dates: Sep 2018 – Aug 2022· Results posted
Sponsor: Mirati Therapeutics, Inc.

Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more

TerminatedInterventional · Not applicableNCT03618095 ↗

REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects

Geoffrey W BergmanPI

Intervention: Device: LOTUS Edge Valve System
Dates: Jan 2019 – Mar 2021· Results posted
Sponsor: Boston Scientific Corporation

Aortic Valve Stenosis

TerminatedInterventional · Phase 2NCT03655236 ↗

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease

Harini SarvaPI

Intervention: Drug: K0706 · Other: placebo
Dates: Feb 2019 – Apr 2024· Results posted
Sponsor: Sun Pharmaceuticals Global FZE

Early Parkinson Disease

TerminatedInterventional · Phase 2NCT03672292 ↗

A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

Alexander DrelickPI

Intervention: Drug: SCY-078 · Drug: Voriconazole · Other: Oral Placebo Tablets
Dates: Jan 2019 – Mar 2023· Results posted
Sponsor: Scynexis, Inc.

Invasive Pulmonary Aspergillosis

TerminatedInterventional · Phase 2NCT03679624 ↗

A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

John AllanPI

Intervention: Drug: Ibrutinib · Drug: Daratumumab
Dates: Jul 2020 – Sep 2020· Results posted
Sponsor: Weill Medical College of Cornell University

Waldenstrom MacroglobulinemiaWaldenstrom's DiseaseWaldenström+5 more

‹ Prev1 2 3 4 5 6 7 8 Next ›